Longeveron is focusing on using its primary treatment, Lomecel-B, to fight a rare pediatric heart birth defect that devastates families but continues to receive good FDA news regarding its treatment for Alzheimer's Disease. The company announced that its primary drug, laromestrocel, has been approved for a Phase 2 trial for the treatment of Pediatric Dilated Cardiomyopathy. This expands the potential market for treatment and provides hope for thousands of patients.
